Oral Cannabinoid Patent Race
Just this past week, six (6) patent applications (U.S. Patent Pub. Nos. 20200330339, ‘378, ‘423, ‘424, ‘425, & ‘602) were published in regards to oral cannabis compositions by five different companies: APIRx Pharmaceutical USA, LLC, ICD Pharma Ltd., MedCan Pharma A/S, PharmaCytics B.V., and NordicCan A/S.
Cannabis is gaining popularity quickly with more people finding ways to incorporate it into their lifestyles. Not everyone will be willing to smoke dry cannabis products, giving way to the development of oral solutions – especially for the medical cannabis industry.
Of the five assignees, APIRx Pharmaceuticals USA is the most active in cannabis composition filings right behind cannabis giants GW Pharmaceuticals plc and MannKind Corporation. The other four assignees will need to increase their filing activity if they want to become a leader in the space – or they could be like cannabis giant Aurora Cannabis Inc.
Explore the vast portfolio of GW Pharmaceuticals and MannKind Corporation using the Magic Number® Cannabis Patent Forecast® to see what these five companies are up against. Start your free trial today!
Related Posts
Cannabis Popularity Soars Along With Tests To Detect It
The Duquenois Levine Test is used in the field by law enforcement officers to test for THC presence in a suspected sample. The problem with…
Hound Labs, Cannabix and Vox Heat Up the Marijuana Breathalyzer Market
At the start of April 2021, Patent Forecast® released an insight going over some of the big name competitors getting their foot in the door…
Driving While High? Cannabis Sobriety Testing Heats Up
What’s the future of cannabis innovation? We see things before they happen using our Patent Forecast®. One of those is the development of…